Lung microbiome mediates the progression from chronic obstructive pulmonary disease to lung cancer through inflammation

Yi Chuan. 2021 Jan 20;43(1):30-39. doi: 10.16288/j.yczz.20-315.

Abstract

Lung microbiome exists in the respiratory tract and parenchymal tissues. It mediates lung injury through a variety of mechanisms, including bacterial disturbance, metabolites, inflammatory response, immune response, and genotoxicity. Accumulating evidences suggest that changes in lung microbiome correlates with chronic obstructive pulmonary disease (COPD) and lung cancer, and the microbiome promotes the progression from COPD to lung cancer. In this review, we mainly introduce the impairment of the homeostasis of the lung microbiome and its inflammation that leads to COPD and lung cancer, then focus on how the microbiome mediates the progression from COPD to lung cancer through inflammatory response. The review may provide a new theoretical basis for clinical prevention, optimal treatment strategy and design of new drugs for COPD and lung cancer.

肺部微生物组存在于呼吸道和实质组织中,通过菌群紊乱、代谢产物、炎症反应、免疫反应、基因毒性等方面介导肺部损伤。随着肺部微生物组的深入研究,发现肺部微生物组的相关活动与慢性阻塞性肺疾病(chronic obstructive pulmonary disease, COPD)和肺癌息息相关,能够促使COPD向肺癌的转变。本文主要介绍了肺部微生物组稳态及其通过炎症反应导致COPD和肺癌,重点探讨了肺部微生物组如何通过炎症反应介导COPD转化为肺癌,以期为COPD和肺癌的临床预防、优化治疗以及新型药物设计提供新的理论依据。.

Keywords: chronic obstructive pulmonary disease; diversity; inflammation; lung cancer; lung microbiome.

Publication types

  • Review

MeSH terms

  • Disease Progression
  • Humans
  • Inflammation / microbiology*
  • Lung / microbiology*
  • Lung Neoplasms / microbiology*
  • Microbiota*
  • Pulmonary Disease, Chronic Obstructive / microbiology*